|
Salmon vaccination. (Photo: Pharmaq)
SRS vaccine now available for the Chilean salmon industry
(CHILE, 2/24/2016)
The National Agriculture and Livestock Service (SAG) has taken an important step in support of the Chilean salmon farming industry authorizing the provisional marketing of a vaccine to fight Salmon Rickettsial Septicaemia (SRS) Syndrome, a disease that causes serious economic losses to the sector.
The authorized vaccine, Alpha Ject LiVac® SRS, was developed by Pharmaq and is the only first live attenuated vaccine against SRS syndrome.
The President of Pharmaq, Morten Kr. Nordstad, explained, “Our innovative drive is based on the aquaculture industry's need to produce safe and healthy seafood. We are confident that this ground-breaking vaccine will be an important tool to help fight SRS.
“This is a highly requested product by the industry and will help achieve more predictable and reliable fish production," he added.
For Pharmaq, the approval by the Chilean authority to sell the attenuated live vaccine, which is already available in the market, is an important technology milestone for the salmon farming sector.
The company notes that the vaccine represents many years of research, development and documentation to ensure a high quality product to provide a high level of protection as well as being safe for the fish and the environment.
Salmon Rickettsial Septicaemia (SRS) or Piscirickettsiosis is caused by the bacterium Piscirickettsia salmonis, and it is considered the most serious disease the Chilean aquaculture industry faces.
Since its appearance in 1989, it has affected all three species farmed in Chile: Atlantic salmon, rainbow trout and coho salmon.
editorial@seafood.media
www.seafood.media
Information of the company:
|
Address:
|
Production facility - Skogmo Industriområde
|
|
City:
|
Overhalla
|
|
State/ZIP:
|
(NO-7863)
|
|
Country:
|
Norway
|
|
Phone:
|
+47 2329 8500
|
|
Fax:
|
+47 2329 8501
|
|
E-Mail:
|
info@pharmaq.no
|
More about: 
|
|
|
|
Print
